Galectin Therapeutics Inc stock is traded at $3.20, with a volume of 102,841. It is down -2.74% in the last 24 hours and down -17.31% over the past month. Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
Previous Close:
$3.29
Open:
$3.28
24h Volume:
102,841
Relative Volume:
0.51
Market Cap:
$322.72M
Revenue:
-
Net Income/Loss:
-$26.25M
P/E Ratio:
-
EPS:
-$0.4099
Net Cash Flow:
-$20.05M
1W Performance:
+7.20%
1M Performance:
-17.31%
6M Performance:
+42.22%
1Y Performance:
-45.11%
1-Day Range:
$3.07$3.53
1-Week Range:
$2.90$3.53
52-Week Range:
$2.03$7.13
Galectin Therapeutics Inc Stock (GALT) Company Profile
Name
Galectin Therapeutics IncSector
HealthcareIndustry
BiotechnologyPhone
678-620-3186Address
4960 PEACHTREE INDUSTRIAL BOULEVARD, NORCROSS, GA, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS